Drug
AK 105
AK 105: highest development phase Phase 1, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK-105 NCT03352531 | Phase 1 | Advanced Cancer |
Latest
No recent events.
Follow AK 105 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.